Literature DB >> 36180654

Retroperitoneal laparoscopic renal biopsy: an 8 year experience at a single centre.

Guming Zou1, Haixin Chen2, Xiaofeng Zhou2, Wenge Li1, Li Zhuo3.   

Abstract

PURPOSE: To present our experience and outcome of consecutive laparoscopic renal biopsy (LRB) in a series of Chinese patients over an 8 year period.
METHODS: Between January 1, 2013, and December 31, 2020, 104 patients (M/F 71/33, age 43.6 ± 16.0 years) were enrolled. All patients underwent LRB for various indications, e.g., dialysis dependence (33.7%), serum levels of creatinine ≥ 442 μmol/L (20.2%), morbid obesity (18.3%), uncontrolled severe hypertension (14.4%), aberrant renal anatomy (5.8%), solitary kidney (2.9%), deaf-mutes (2.9%), failed percutaneous biopsy (1.0%) and patient choice (1.0%). The kidney was approached via the laparoscopic retroperitoneal route using a three-port technique. Then, 16-gauge true-cut needle biopsy was performed and haemostasis was achieved by compression. Topical collagen mesh was used if necessary.
RESULTS: Renal tissue was obtained in all cases. The operative time and amount of blood loss were significantly (P < 0.05) lower in 2017-2020 than 2013-2016 [42.6 ± 1.5 min and 9.6 ± 0.7 mL, respectively (n = 61) vs. 51.2 ± 1.3 min and 14.4 ± 0.9 mL, respectively (n = 43)], while the hospital stay was not significantly different between the two periods. The rate of tissue adequacy and median number of glomeruli were significantly higher in 2017-2020 than 2013-2016 [100% and 52 (IQR 24-94), respectively vs. 93% and 35 (IQR 6-98), respectively). Two postoperative complications occurred in the first 4 years: disseminated intravascular coagulation (DIC) during the operation and injury at the hilum of the kidney (n = 1 each). The renal pathological diagnoses were also complex: 70.2% of the cases were independent pathological types, including IgA nephropathy (IgAN) (13.5%), Henoch-Schönlein purpura nephritis (HSPN) (2.9%), focal segmental glomerulosclerosis (FSGS) (9.6%), membranous glomerulonephritis (MN) (1.9%), lupus nephritis (LN) (3.8%), crescentic glomerulonephritis (CreGN) (7.7%), diabetic nephropathy (DN) (10.6%), tubulointerstitial nephritis (TIN) (11.5%) and malignant hypertensive nephropathy (MHTN) (8.7%). However, the rates of combinations of two and three pathological types were 25.0% and 4.8%, respectively.
CONCLUSION: Retroperitoneal LRB is a safe, reliable, minimally invasive alternative for patients in whom PRB in not feasible. As a helpful supplement to PRB, it may be necessary to use this technique more often in the future.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Laparoscopy; Renal biopsy; Retroperitoneal approach

Year:  2022        PMID: 36180654     DOI: 10.1007/s11255-022-03324-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.266


  6 in total

1.  Proposed classification of complications of surgery with examples of utility in cholecystectomy.

Authors:  P A Clavien; J R Sanabria; S M Strasberg
Journal:  Surgery       Date:  1992-05       Impact factor: 3.982

2.  Biopsies and the Completion of certain Surgical Procedures.

Authors:  N B Gwyn
Journal:  Can Med Assoc J       Date:  1923-11       Impact factor: 8.262

Review 3.  Renal biopsy for medical renal disease: indications and contraindications.

Authors:  Jathin Bandari; Thomas W Fuller; Robert M Turner Іі; Louis A D'Agostino
Journal:  Can J Urol       Date:  2016-02       Impact factor: 1.344

4.  Retroperitoneal laparoscopic renal biopsy.

Authors:  J J Keizur; M Tashima; S Das
Journal:  Surg Laparosc Endosc       Date:  1993-02

5.  Open renal biopsy. Surgical technique and results.

Authors:  J H Thomas; G E Pierce; A S Hermreck
Journal:  Am Surg       Date:  1983-07       Impact factor: 0.688

6.  [PROCEDURE AND FEASIBILITY OF LAPAROSCOPIC RENAL BIOPSY].

Authors:  Yuka Ichibagase; Kohei Takahara; Saya Kurata; Hiroaki Kakinoki; Kazuma Udo; Maki Nanri; Shohei Tobu; Yuji Tokuda; Mitsuru Noguchi; Jiro Uozumi
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  2015-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.